Vanguard Group Inc Clearside Biomedical, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,363,061 shares of CLSD stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,363,061
Previous 2,806,607
19.83%
Holding current value
$1.45 Million
Previous $2.58 Million
4.18%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CLSD
# of Institutions
48Shares Held
11.8MCall Options Held
0Put Options Held
0-
Act Capital Management, LLC Wayne, PA2.2MShares$944,9163.43% of portfolio
-
Carmignac Gestion Paris, I01.51MShares$648,5870.02% of portfolio
-
Black Rock Inc. New York, NY798KShares$343,1980.0% of portfolio
-
Geode Capital Management, LLC Boston, MA790KShares$339,8600.0% of portfolio
-
Gsa Capital Partners LLP London, X0534KShares$229,4150.03% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $25.9M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...